25 results about "Vaccinia" patented technology

The present invention relates to a primer set, composition, kit for the detection of vaccinia virus for the detection and quantification of vaccinia virus and an analysis method using the same, and the primer set for the detection of vaccinia virus has a shorter analysis period and superior sensitivity and specificity compared to the conventional virus quantitation method, so that when real-time PCR applied to such a primer set is performed, it is possible to detect and quantify vaccinia virus more quickly and accurately in real time.

Exemplary methods, compositions, kits and uses thereof for treating neoplasia are provided. For example, a method can be provided for treating neoplasia in a subject, including administering to the subject a VRK2 (vaccinia-related kinase 2) inhibitor, alone or in combination with an inhibitor of Programmed cell death receptor-1 (PD-1). The exemplary methods, compositions and kits may improve cancer immunotherapy.

Described herein are methods and compositions for treating a disease, e.g. cancer (including solid tumors), using glial cells (e.g. microglia cells and / or astrocytes) and / or macrophages (e.g., CNS-associated macrophages) infected with an oncolytic virus (e.g., vaccinia virus). The methods and compositions provided herein demonstrate a synergistic anti-cancer effect.

Provided herein is a method for efficiently capping RNA in vitro. In some embodiments the capping reaction may be done at high temperature using Vaccinia capping enzyme or a variant thereof. In other embodiments, the capping reactions may comprise a capping enzyme from a large virus of amoeba, e.g., Faustovirus, mimivirus or moumouvirus, or a variant thereof. Compositions and kits for practicing the method are also provided.

This invention relates to the fields of biotechnology and targeted therapy, specifically to a recombinant construct, a recombinant oncolytic virus, its construction method, and its applications. The recombinant oncolytic virus CD19 BIKE is prepared by inserting exogenous genes for CD16 and CD19 into the genome of an oncolytic vaccinia virus. The antibodies secreted by this recombinant virus can not only bridge NK cells and CD19-positive B-cell lymphoma cells, increasing the contact between NK cells and tumor cells and their accumulation within tumor tissue, but also synergize with the tumor-lysing effect of the oncolytic virus, breaking down the stromal barrier, reshaping the tumor microenvironment, and enhancing therapeutic efficacy.

Contemplated compositions, devices, and methods comprise immunodominant antigens from selected human pathogens (Burkholderia pseudomallei, Borrelia burgdorferi, Brucella melitensis, Chlamydia muridarum, Coxiella burnetii, Francisella tularensis, human Herpes virus 1 and 2, Mycobacterium tuberculosis, Plasmodium falciparum, and Vaccinia virus) can be used as a vaccine, as diagnostic markers, and as therapeutic agents. In particularly preferred aspects, the antigens have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and have a known association with a disease parameter.

To provide a method for efficiently capping RNA in vitro.SOLUTION: In some embodiments, the capping reaction can be done at high temperature using Vaccinia capping enzyme or variants thereof. In other embodiments, the capping reaction may comprise capping enzymes from amoebic large viruses, such as Faust, Mimivirus, or Moumouvirus, or variants thereof. Compositions and kits for practicing the methods are also provided.SELECTED DRAWING: None

The invention belongs to the technical field of biological medicines, and provides a heat stress protein HSP70 inhibitor and application thereof in preparation of antitumor drugs. Experiments prove that the heat stress protein HSP70 inhibitor can enhance the replication capacity of oncolytic viruses in tumor cells and enhance the anti-tumor immune activation capacity at the same time; the invention further proves that the oncoVV-shHSP70 can effectively inhibit the expression of the HSP70 protein, so that the survival rate of various cancer cells can be obviously reduced, the effect is obviously superior to that of a control virus oncoVV only lacking the TK gene, and meanwhile, the oncoVV-shHSP70 can promote the infiltration of CD8 < + >-T cells in tumor tissues. The HSP70 inhibitor can be used for preparing an anti-tumor virus drug, particularly, the HSP70 inhibitor and the vaccinia virus are recombined into a recombinant vector, the advantages of the HSP70 inhibitor and the vaccinia virus can be combined, a new target spot is provided for virus treatment of tumors, and the HSP70 inhibitor has a wide clinical application prospect.

The present invention relates to recombinant Modified Vaccina Virus Ankara (MVA) encoding Epstein-Barr virus (EBV) antigens, wherein surface glycoprotein 350 (EBV gp350) and glycoprotein gH (EBV gH) are fused to subunits of self-assembling multimeric protein particle PdhC (acetyltransferase of pyruvate dehydrogenase (PDH) complex) or DPS (DNA binding protein from starved cells).

To provide newly adapted and / or more potent viruses and / or virus vectors useful for treatment of human diseases.SOLUTION: Disclosed herein is a novel immune-modulating vaccinia virus strain (IOVA) and derivatives thereof with high replication efficiency for use in the medicine. The novel vaccinia virus strain IOVA and derivatives thereof, vectors and recombinants have an ability to replicate in a mammal cancer line and being lytic or, in the case of cancer cells, oncolytic, and elicit an increased capacity to destroy cell-cycle activated cells and / or tumor cells, compared with the gold standard Vaccinia virus WR.SELECTED DRAWING: None

The present invention relates to recombinant modified vaccinia virus Ankara (MVA) encoding the spike (S) protein or portions thereof, such as the receptor binding domain (RBD), and additional antigenic sequences derived from other proteins of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 19 (COVID-19).

The disclosure provides recombinant vaccinia vectors (rVACV) comprising variant A34R proteins. As compared to a vaccinia vector comprising the wild-type A34R protein, the rVACVs described herein exhibit increased production of extra-cellular enveloped virion (EEV). Also described herein are variant A34R proteins, nucleic acids encoding variant A34R proteins, and cells containing the nucleic acids encoding variant A34R proteins. The disclosure further provides methods of producing rVACV by culturing the cells containing the nucleic acids encoding variant A34R proteins and purifying the rVACV. Furthermore, provided are methods of treating a cancer in a subject by administering to the subject rVACVs comprising the variant A34R proteins.

The invention relates to the field of biotechnology and targeted therapy, in particular to a recombinant construct, a recombinant oncolytic virus and a construction method and application of the recombinant oncolytic virus. The recombinant oncolytic virus CD19 BIKE is prepared by inserting exogenous genes of CD16 and CD19 into an oncolytic vaccinia virus genome. The antibody secreted by the recombinant virus not only can bridge NK cells and CD19 positive B cell lymphoma cells to increase contact between the NK cells and tumor cells and accumulation in tumor tissues, but also can cooperate with oncolytic viruses to dissolve tumors, break matrix barriers, remodel tumor microenvironments and improve treatment effects.

The use of extract from rabbit skin inflamed by vaccinia virus for treating Parkinson's disease or restoring neurological function of the brain or alleviating damage to neurological function of the brain in a patient suffering from Parkinson's disease is provided. The extract from rabbit skin inflamed by vaccinia virus can be Lepalvir.

The invention relates to application of a vaccinia virus inflammatory rabbit skin extract in preparation of an HPV (human papillomavirus) inhibitor.

The invention relates to the technical field of biology, in particular to a recombinant oncolytic vaccinia virus, a preparation method thereof and application of the recombinant oncolytic vaccinia virus in preparation of drugs for preventing or treating tumors. According to the invention, the mIL-4 is inserted into the oncolytic vaccinia virus, so that the oncolytic vaccinia virus replicates in tumor cells and lyses the cells, and the mIL-4 protein is expressed while the tumor cells are killed, thereby improving the treatment effect.

Provided herein is a method for efficiently capping RNA in vitro. In some embodiments the capping reaction may be done at high temperature using Vaccinia capping enzyme or a variant thereof. In other embodiments, the capping reactions may comprise a capping enzyme from a large virus of amoeba, e.g., Faustovirus, mimivirus or moumouvirus, or a variant thereof. Compositions and kits for practicing the method are also provided.

The present invention relates to a process for preparing recombinant Modified Vaccina Virus Ankara (MVA) using bacterial artificial chromosome (BAC) based permanent dominant selection.

The invention provides application of an improved vaccinia virus Ankara (MAV) in preparation of a medicine for resisting tumors with low ZAP expression, and belongs to the technical field of biological medicines. The invention relates to application of MAV in preparation of drugs for preventing and / or treating tumors with low ZAP expression. In view of the fact that MVA targets cancer cells with low expression of ZAP and has good oncolytic property, the invention further provides an anti-cancer drug, and active ingredients of the anti-cancer drug comprise the improved vaccinia virus Ankara and at least one of the following reagents: a reagent for knocking out or inhibiting ZAP gene expression. In-vivo and in-vitro experiment results show that the MAV is used as a selective oncolytic virus to target cancer cells with low expression of ZAP and clear the cancer cells, and a new thought is provided for prevention and treatment of tumors.

The invention discloses an air circulation device for a vaccinia virus production workshop, which comprises a production workshop main body, an air supply mechanism is arranged at the top of the production workshop main body, a production station is arranged in the production workshop main body, an air outlet is arranged in the production station, an air exhaust mechanism is arranged at the bottom of the air outlet, and an air outlet is arranged at the bottom of the air exhaust mechanism. The exhaust mechanism is arranged on the outer side of the bottom of the production workshop body, and a pressure difference control mechanism is arranged on the production station. By installing the multi-stage filtering mechanism, air is filtered by the primary filter to block large particles, and enters the high-efficiency filter after particles with the size of 1-5 microns are filtered out by the medium-efficiency filter, particles with the size smaller than 1 micron are filtered out by the high-efficiency filter, and it is ensured that the air entering the core production area is sterile and dustless through multi-stage filtering.

The application provides an antibody or an antigen-binding fragment thereof capable of specifically binding to CD47. The application also provides a recombinant oncolytic virus, which is operatively inserted or comprises a gene coding sequence of an anti-CD47 antibody or a CD47 ligand. According to the application, the anti-CD47 antibody comprises an Fc mutant with A330L / I332E mutation (ALIE antibody), that is, the anti-CD47 antibody is alphaCD47-Fc (ALIE). The application provides a preparation method of the recombinant oncolytic virus. The application also provides a use of the recombinant oncolytic virus for preparing an anti-tumor drug. The application combines the gene therapy of tumors with the oncolytic effect, and prepares a vaccinia virus Tianlu strain capable of efficiently expressing an alphaCD47-Fc (ALIE) gene, thereby significantly improving the effect of tumor immunotherapy.

Provided herein is a method for efficiently capping RNA in vitro. In some embodiments the capping reaction may be done at high temperature using Vaccinia capping enzyme or a variant thereof. In other embodiments, the capping reactions may comprise a capping enzyme from a large virus of amoeba, e.g., Faustovirus, mimivirus or moumouvirus, or a variant thereof. Compositions and kits for practicing the method are also provided.

The present disclosure belongs to the field of biological medicines, and relates to use of DR-18 and an oncolytic vaccinia virus in the preparation of an anti-tumor drug. The present disclosure has found for the first time that combined use of the oncolytic vaccinia virus and DR-18 has a synergistic anti-tumor effect. The present disclosure also relates to an anti-tumor pharmaceutical composition comprising an oncolytic vaccinia virus and DR-18, and use of an oncolytic vaccinia virus and DR-18 in the preparation of an anti-tumor drug.

An object of the present invention is to provide an N-acetylgalactosaminyltransferase expression promoter containing an extract from inflamed tissues inoculated with vaccinia virus.SOLUTION: In the present invention, it was shown that the extract from inflamed tissues inoculated with vaccinia virus promotes the expression of N-acetylgalactosaminyltransferase in intervertebral disc cells. Therefore, the extract from inflamed tissues inoculated with vaccinia virus or a preparation containing the same is useful as an agent for promoting the expression of N-acetylgalactosaminyltransferase in intervertebral disc cells.SELECTED DRAWING: Figure 1

The present invention relates to the therapeutic use of extract from rabbit skin inflamed by vaccinia virus. More specifically, the present invention relates to the use of extract from rabbit skin inflamed by vaccinia virus for treating Alzheimer's disease. In addition, the present invention relates to the use of extract from rabbit skin inflamed by vaccinia virus for protecting neurological function of the brain or alleviating damage to neurological function of the brain in a patient suffering from Alzheimer's disease. In addition, the extract from rabbit skin inflamed by vaccinia virus can be Lepalvir.